Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study건강한 성인에서 이종 및 동종 불활성화 및 아데노바이러스 매개 COVID-19 백신 요법의 안전성 및 면역원성: 전향적 코호트 연구Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Adults adverse event adverse events Antibody Response AstraZeneca ChAdOx1 ChAdOx1-S circulating variants combinations CoronaVac country COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Efficacy Evidence evidence of followed by group groups healthy Heterologous heterologous adenoviral vector heterologous vaccine homologous IgA response immune response immune responses immunized immunogenicity inactivated Inactivated vaccine interferon gamma Mild neutralizing activities Neutralizing activity prospective cohort study reactogenicity Receptor-binding domain referred to regimen Safety Serious Adverse Event Serious Adverse Events supply shortage vaccination Vaccine variants variants of concern Viral viral vectored. wild-type [DOI] 10.1080/21645515.2022.2029111 PMC 바로가기 [Article Type] Article
Assessing the reporting quality of randomized controlled trials on COVID-19 vaccines: a systematic reviewCOVID-19 백신에 대한 무작위 대조 시험의 보고 품질 평가: 체계적인 검토Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] 임상, [키워드] adverse effect Analysis analysis of variance Assessing CONSORT CONSORT statement controlled trials COVID-19 COVID-19 vaccine COVID-19 vaccines criteria current database effective evaluated Evidence groups independent indicate indicated median Mortality no significant difference predicted Randomized Randomized controlled trial Randomized controlled trials RCT RCTs reported Reporting Reporting quality review. Standard systematic review Univariate analysis variance variety [DOI] 10.1080/21645515.2022.2031453 PMC 바로가기 [Article Type] Article
Association of trace element status in COVID-19 patients with disease severityResearch article Published on 2022-12-012022-10-05 Journal: Journal of trace elements in medicine and biology [Category] COVID19(2023년), SARS, 변종, [키워드] Anti-inflammatory antioxidant clinical condition clinical symptom conditions coronavirus coronavirus disease COVID-19 COVID-19 patient COVID-19 severity Critical Cu death died disease severity evaluated Fe four group groups I immune response immune system Infection Mg Mild symptom new SARS-CoV-2 no difference Patient reduce risk SARS-COV-2 infection Se Serum level severity severity of symptoms shown significant difference the patient Trace element trace elements Zn [DOI] 10.1016/j.jtemb.2022.127055 [Article Type] Research article
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial재조합 인터페론 무장 융합 단백질 백신(V-01)을 사용한 SARS-CoV-2에 대한 이종 부스팅의 효능: 무작위, 이중 맹검 및 위약 대조 3상 시험Clinical Trial Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] adverse event antibody assigned booster clinical trial common adverse event conducted COVID-19 vaccine COVID-19 vaccines dose double-blind dramatic increase Efficacy elicit eligible fatigue Fever fusion protein groups headache healthy Heterologous heterologous boosting Humoral immunity Identifier Immunity inactivated Inactivated vaccine Inactivated Vaccines Inc injection injection site intention-to-treat principle Malaysia Mild-to-moderate Neutralizing Neutralizing antibodies occurred Older omicron Omicron variant over Pain participant Participants Placebo placebo-controlled primary endpoint Randomized Randomly receive regimen robust Safe SARS-CoV-2 SARS-COV-2 infection second dose Serious Adverse Events subunit Subunit vaccine Subunit vaccine. Surveillance symptomatic SARS-CoV-2 infection the epidemic titre Trial Trial registration V-01 Vaccine vaccine efficacy variant virus-neutralizing antibodies was measured were assessed [DOI] 10.1080/22221751.2022.2088406 PMC 바로가기 [Article Type] Clinical Trial
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Article Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome Beta Blood caused clinically Concentration coronavirus COVID-19 creatine phosphokinase CT-P63 deaths declining Delta demonstrated detectable dose double-blind evaluated groups healthy volunteer Immunity in vitro in vivo Infection Infectious virus lung monoclonal monoclonal antibody morbidity and mortality mutated variant Neutralizing Neutralizing activity neutralizing antibody neutralizing antibody. omicron pandemic parallel-group participant peaked phase Placebo placebo-controlled Preclinical prevalent Prophylactic Randomized reduced respiratory tract Safe SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants of concern Serious Adverse Events significantly single ascending dose study drug TEAE titre Tolerability Transgenic mouse treated Treatment treatment-emergent adverse event vaccination variants variants of SARS-CoV-2 wild-type [DOI] 10.1080/22221751.2022.2117094 PMC 바로가기
COVAD survey 2 long-term outcomes: unmet need and protocolArticle Published on 2022-12-012022-11-15 Journal: Rheumatology International [Category] 치료제, [키워드] adverse event antiviral drug approach approved Autoimmune diseases baseline booster doses cohorts COVID-19 COVID-19 infection COVID-19 vaccine disease Effect effort groups help Heterologous immune modulation Immunity IMPROVE long-term adverse effects pandemic protocol reduce registries risk syndrome synergistic Tolerability translation unmet need vaccination vaccination. Vaccine while [DOI] 10.1007/s00296-022-05157-6 PMC 바로가기
The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFα blockadeArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Activation acute respiratory syndrome alteration analysed anti-SARS-CoV-2 anti-SARS-CoV-2 IgG anti-TNF-α appear Autoimmune Autoimmune diseases blockade bystander Cell changes in chronic inflammatory disease Cohort comparable Control coronavirus COVID-19 Decline drugs Effect Efficacy ELISA flow cytometry groups healthy humoral immune response IgG immune cell populations immune response immunoblot investigated less Live virus Necrosis Neutralization assay neutralize neutralizing antibody neutralizing capacity Older omicron Patient patients plasma Plasma cell recipient reduced response SARS-CoV-2 second vaccination significantly T cell subset titre TNF-α TNFα tumor necrosis factor inhibitors tumor necrosis factor-α vaccination vaccination. Vaccine variants of concern virus VoC was increased while [DOI] 10.1002/jmv.28063 PMC 바로가기
Comparison of clinical features and perinatal outcomes between pre-variant and post-variant periods in pregnant women with SARS-CoV-2: analysis of 1935 casesArticle Published on 2022-12-012022-11-16 Journal: Archives of gynecology and obstetrics [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome Analysis city Clinical characteristics clinical feature Complication coronavirus correlation Course COVID-19 COVID-19 variants Critical case demographic disease severity Features groups ICU admission include Mortality NICU admission Obstetric obstetric complications outcome Pregnancy pregnant patients pregnant women preterm delivery prospective cohort study Respiratory Support SARS-CoV-2 SARS-CoV-2. significant increase significantly higher significantly increased statistically significant the disease [DOI] 10.1007/s00404-022-06493-5 PMC 바로가기
Altered kidney function induced by SARS-CoV-2 infection and acute kidney damage markers predict survival outcomes of COVID-19 patients: a prospective pilot studySARS-COV-2 감염 및 급성 신장 손상 마커에 의해 유도 된 변경된 신장 기능 COVID-19 환자의 생존 결과를 예측합니다 : 전향 적 파일럿 연구Article Published on 2022-12-012022-08-31 Journal: Renal failure [Category] COVID19(2023년), SARS, 바이오마커, [키워드] acute kidney Acute kidney injury adjusted Advancing age Altered Analysis association Biomarker chronic Chronic kidney disease collaboration Comorbidities Comorbidity Control coronavirus disease Coronavirus disease 2019 covariate covariates COVID-19 COVID-19 patient COVID-19 patients creatinine Cumulative rates cystatin C death demonstrated elevated examined group groups Hospitalized ICU intensive care intensive care unit investigated Kaplan-Meier method kidney kidney damage Kidney disease Kidney function Kidney function tests Kidney injury literature marker morbidity multivariable Cox regression outcome participant pilot study predict Predictive Predictive value Proteinuria retained risk factor Risk factors SARS-COV-2 infection serum serum creatinine Sex significant difference statistically subject survival survival analysis survival analysis. the Kaplan-Meier method Treatment Urine with COVID-19 [DOI] 10.1080/0886022X.2022.2032743 PMC 바로가기 [Article Type] Article
Assessing the transition of COVID-19 burden towards the young population while vaccines are rolled out in China중국에서 백신이 출시되는 동안 젊은 인구에 대한 COVID-19 부담의 전환 평가Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] absence Admissions age Assessing cause children China Chinese coronavirus disease Coronavirus disease 2019 Coverage COVID-19 deaths decrease Delta delta variant disease Effectiveness effort eligible Epidemics fatality groups highlight Hospitalization hospitalizations incidence include individual Infants Infection intensive care lineages novel Novel coronavirus novel coronavirus disease Novel coronavirus disease 2019 Older age over SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 transmission symptomatic infection symptomatic infections target population transition transition of disease burden Transmission triggered vaccinated against COVID-19 vaccination vaccination. Vaccine widespread [DOI] 10.1080/22221751.2022.2063073 PMC 바로가기 [Article Type] Article